Correction to: Scientific Reports https://doi.org/10.1038/s41598-021-99184-1, published online 06 October 2021
The original version of this Article contained an error in Figure 3 and 4 where the graph for panel C was omitted. The original Figures 3 and 4 and accompanying legends appear below.
Synergism of ivacaftor (VX-770) and elexacaftor (VX-445) in potentiating G551D-CFTR in FRT cells. (A) Representative It recordings of FRT cells expressing human G551D-CFTR showing acute actions of VX-770 and VX-445. (B–C) Changes in It after acute addition of VX-770 in the absence and presence of VX-445 (B) and in response to the acute addition of VX-445 in the absence and presence of VX-770 (C). (D–E) Changes in It after the additions of test compounds for the experiment presented in (A). G551D-CFTR mediated It is greatest after acute potentiation by both VX-770 and VX-445. (F) Representative It recordings of FRT cells expressing human G551D-CFTR treated for 24 h with DMSO, VX-770, and/or VX-445. (G) Changes in It after the additions of test compounds for the experiment presented in (F). G551D-CFTR mediated It is greatest after chronic treatment by both VX-770 and VX-445. See SI for additional experimental details and for supporting data. All data are presented as mean ± standard error. Bars with different letters (A, B, C…) are significantly different from each other (ANOVA; P < 0.05). Asterisks indicate specific P values: ****P < 0.0001.
Synergism of ivacaftor (VX-770) and elexacaftor (VX-445) in potentiating G551D-CFTR in HNE cells. (A) Representative It recordings of G551D-HNE cells showing acute actions of VX-770 and VX-445. (B–C) Changes in It after acute addition of VX-770 in the absence and presence of VX-445 (B) and in response to the acute addition of VX-445 in the absence and presence of VX-770 (C). (D–E) Changes in It after the additions of test compounds for the experiment presented in (A). G551D-CFTR mediated It is greatest after acute potentiation by both VX-770 and VX-445. (F) Representative It recordings of G551D-HNE treated for 24 h with DMSO, the double combination of VX-770 and VX-445, or the triple combination of VX-661, VX-770, and VX-445 (i.e., Trikafta). (G) CFTRinh-172 inhibited It for the experiment presented in (F). See SI for additional experimental details and for supporting data. All data are presented as mean ± standard error. Bars with different letters (A, B, C…) are significantly different from each other (ANOVA; P < 0.05). Asterisks indicate specific P values: ****P < 0.0001.
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shaughnessy, C.A., Zeitlin, P.L. & Bratcher, P.E. Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep 11, 21295 (2021). https://doi.org/10.1038/s41598-021-00539-5
Published:
DOI: https://doi.org/10.1038/s41598-021-00539-5
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
